VECTORMUNE® HVT-IBD | BCH-LMO-SCBD-105260 | Living Modified Organism | Biosafety Clearing-House


Living Modified Organism (LMO)

Decisions on the LMO Risk Assessments  
last updated: 28 Jan 2014
Living Modified Organism identity
The image below identifies the LMO through its unique identifier, trade name and a link to this page of the BCH. Click on it to download a larger image on your computer. For help on how to use it go to the LMO quick-links page.
  • - Person: Dr Alexis Henry Gaetan Goux | BCH-CON-SCBD-105170-2
    Dr Alexis Henry Gaetan Goux
    President of CIBio,
    Rua Manuel Joaquim Filho, 303 Pulínia - SP
    Paulínia, São Paulo
    13140-000, Brazil
    Phone: 551938337700,
    Fax: 55193833-7722,
    Related Organization
    Ceva Saúde Animal Ltda (CEVA)
    Private sector (business and industry)
    Rua Manuel Joaquim Filho, 303 Pulínia - SP
    Paulínia, São Paulo
    13140-000, Brazil
    Phone: 551938337700,
    Fax: 55193833-7722,
VECTORMUNE® IBD  is a chicken vaccine that contains a genetically engineered Marek’s Disease virus of serotype 3 (turkey Herpesvirus or HVT) expressing Infectious Bursal Disease key protective antigens, therefore providing immunity against IBD.
The term “Recipient organism” refers to an organism (either already modified or non-modified) that was subjected to genetic modification, whereas “Parental organisms” refers to those that were involved in cross breeding or cell fusion.
Characteristics of the modification process
  • Other (Homologous Recombination)
Some of these genetic elements may be present as fragments or truncated forms. Please see notes below, where applicable.
  • BCH-GENE-SCBD-105217-2 Beta-actin gene promoter | (Chicken, CHICK)
  • BCH-GENE-SCBD-105223-1 Viral Protein 2 gene | (Gumboro virus)
    Protein coding sequence | Production of medical or pharmaceutical compounds (human or animal) (Vaccines)
A 2.9 kb region of the HVT genome was inserted into the pUC18 vector. This fragment contained the incomplete open reading frame (ORF) of UL44 and the complete ORFs of UL45 and UL46 from the HVT genome.

The chicken beta-actin promoter and transcription termination sequences from SV40 and UL46 were inserted into the HVT genoming DNA fragment.

The VP2 gene from the Delaware Variant of the IBDV was amplified from viral RNA using RT-PCR and inserted in to the pUC18 vector in between the beta-actin promoter and termination sequences from SV40 and UL46.

This construct and the the parental HVT strain were co-transformed into chicken embryo fibroblasts and incubated under conditions that favour homologous recombination.

Viral particles were cultivated from the chicken embryo fibroblasts and plaques were expanded and screened and selected for the expression of the VP2 gene.
LMO characteristics
  • Vaccine
Detection method(s)
Additional Information
Records referencing this document Show in search
Record type Field Record(s)
Living Modified Organism Related LMO(s) 1
Country's Decision or any other Communication Living modified organism(s) 3
Risk Assessment generated by a regulatory process Living modified organism(s) 3